Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma

2017 ◽  
Vol 153 (8) ◽  
pp. 832 ◽  
Author(s):  
Yasuhiro Nakamura ◽  
Takashi Fujino ◽  
Hiroshi Kagamu ◽  
Taisuke Matsuya ◽  
Yukiko Teramoto ◽  
...  
1994 ◽  
Vol 21 (1) ◽  
pp. 7-15 ◽  
Author(s):  
Wilhelm Stolz ◽  
Thomas Vogt ◽  
Michael Landthaler ◽  
Siegfried Hempfer ◽  
Paul Bingler ◽  
...  

eLife ◽  
2021 ◽  
Vol 10 ◽  
Author(s):  
Andrew S McNeal ◽  
Rachel L Belote ◽  
Hanlin Zeng ◽  
Marcus Urquijo ◽  
Kendra Barker ◽  
...  

Benign melanocytic nevi frequently emerge when an acquired BRAFV600E mutation triggers unchecked proliferation and subsequent arrest in melanocytes. Recent observations have challenged the role of oncogene-induced senescence in melanocytic nevus formation, necessitating investigations into alternative mechanisms for the establishment and maintenance of proliferation arrest in nevi. We compared the transcriptomes of melanocytes from healthy human skin, nevi, and melanomas arising from nevi and identified a set of microRNAs as highly expressed nevus-enriched transcripts. Two of these microRNAs—MIR211-5p and MIR328-3p—induced mitotic failure, genome duplication, and proliferation arrest in human melanocytes through convergent targeting of AURKB. We demonstrate that BRAFV600E induces a similar proliferation arrest in primary human melanocytes that is both reversible and conditional. Specifically, BRAFV600E expression stimulates either arrest or proliferation depending on the differentiation state of the melanocyte. We report genome duplication in human melanocytic nevi, reciprocal expression of AURKB and microRNAs in nevi and melanomas, and rescue of arrested human nevus cells with AURKB expression. Taken together, our data describe an alternative molecular mechanism for melanocytic nevus formation that is congruent with both experimental and clinical observations.


2016 ◽  
Vol 28 (6) ◽  
pp. 777 ◽  
Author(s):  
Ik Jun Moon ◽  
Chong Hyun Won ◽  
Mi Woo Lee ◽  
Jee Ho Choi ◽  
Sung Eun Chang

2021 ◽  
Vol 19 (4) ◽  
pp. 27-33
Author(s):  
Seseg Vitalievna Tsyrenzhapova ◽  
Roman Nikolaevich Belonogov ◽  
Ekaterina Yurievna Sergeeva ◽  
Tatyana Gennagievna Ruksha

2006 ◽  
Vol 33 (2) ◽  
pp. 139-144 ◽  
Author(s):  
L. J. Perez ◽  
P. F. Penas ◽  
M. Atienzar ◽  
A. Garcia-Diez

2012 ◽  
Vol 136 (8) ◽  
pp. 947-955 ◽  
Author(s):  
Wells M. Chandler ◽  
Leslie R. Rowe ◽  
Scott R. Florell ◽  
Mona S. Jahromi ◽  
Joshua D. Schiffman ◽  
...  

Context.—Histologic examination of clinically suspicious melanocytic lesions is very sensitive and specific for the detection of malignant melanoma. Yet, the malignant potential of a small percentage of melanocytic lesions remains histologically uncertain. Molecular testing offers the potential to detect the genetic alterations that lead to malignant behavior without overt histologic evidence of malignancy. Objective.—To differentiate benign melanocytic nevi from malignant melanoma and to predict the clinical course of melanocytic lesions with ambiguous histology using a novel genomic microarray. Design.—We applied a newly developed single-nucleotide polymorphism genomic microarray to formalin-fixed, paraffin-embedded melanocytic lesions to differentiate benign nevi (n  =  23) from malignant melanoma (n  =  30) and to predict the clinical course of a set of histologically ambiguous melanocytic lesions (n  =  11). Results.—For cases with unambiguous histology, there was excellent sensitivity and specificity for identifying malignant melanoma with this genomic microarray (89% sensitivity, 100% specificity). For cases with ambiguous histology, the performance of this genomic microarray was less impressive. Conclusions.—Without microdissection and with quantities of DNA one-tenth what is required for more commonly used microarrays, this microarray can differentiate between malignant melanoma and benign melanocytic nevi. For histologically ambiguous lesions, longer clinical follow-up is needed to confidently determine the sensitivity and specificity of this microarray. Some of the previous technical hurdles to the clinical application of genomic microarray technology are being overcome, and the advantages over targeted fluorescence in situ hybridization assays currently in clinical use are becoming apparent.


Sign in / Sign up

Export Citation Format

Share Document